PENTA 20 (Odyssey)


Dec, 2021

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children


Authors: A Turkova, E White, HA. Mujuru, AR. Kekitiinwa, CM. Kityo, A Violari, A Lugemwa, TR. Cressey, P Musoke, E Variava, MF. Cotton, M Archary, et al for the ODYSSEY Trial Team

Published in: New England Journal of Medicine


Dec, 2021

Once-daily DTG more effective in treating HIV in children

Tags: ,

The ODYSSEY trial’s final paper Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children has been published in the New England Journal of Medicine. ODYSSEY, sponsored by Penta and funded by ViiV Healthcare, is the first randomised controlled trial to compare the efficacy and safety of dolutegravir-based regimens to non-dolutegravir-based standard-of-care regimens in children and adolescents.

Dolutegravir (DTG) is a drug shown to be highly effective and safe in treating HIV in adults, and ODYSSEY, enrolling more than 700 children from Uganda, South Africa, Zimbabwe, Thailand, UK, Germany, Spain and Portugal, revealed that DTG based treatments in children were more effective and as safe as standard care regimens, with children experiencing fewer adverse effects and better growth. The results of the ODYSSEY substudies played a role in the Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval of once-daily dispersible DTG for children as young as 4 weeks old at a substantially low cost.

There are an estimated 1.7 million children currently living with HIV. Treatment options for children are limited  compared to those available to adults. HIV infection in children is a chronic condition, and without access to antiretroviral treatment, the disease progresses rapidly, increasing the likelihood for the development of AIDS and the risk of suffering AIDS-related deaths.

With the new paediatric DTG regimens, ODYSSEY played a part in ensuring children can begin safe and effective treatment against HIV from a young age. A step closer to the realisation of an AIDS-free generation.


Read the press release by UCL here

Watch the animated abstract here



Dec, 2021

Size of HIV-1 reservoir is associated with telomere shortening and immunosenescence in early-treated European children with perinatally acquired HIV-1


Authors: A Dalzini, G Ballin, S Dominguez-Rodriguez, P Rojo , M.R Petrara, C Foster, N Cotugno, A Ruggiero, E Nastouli, N Klein, S Rinaldi, S Pahwa, P Rossi, C Giaquinto, P Palma , A De Rossi1, and on behalf of EPIICAL Consortium

Published in: Journal of the International AIDS Society

View publication


Dec, 2021

Ethical youth engagement in the HIV response

Tags: ,

Penta youth in collaboration with IAS, have organised a webinar taking place on Thursday, 16 December at 12pm CET (GMT+1) on the theme Invest in our future: How to walk the talk of ethical Youth engagement in the HIV response.

The objectives of the webinar are to showcase best practices for youth participation within the HIV sector, to highlight the current gaps in proactive responses to youth participation models and insight, and to discuss the importance of ethical youth engagement being backed by policies co-produced by young people and key stakeholders to ensure accountability and effectiveness.


Dec, 2021

Diaskin and tuberculin skin test as tuberculosis diagnostics in Russian children: comparative observational study


Authors: Fritschi N, Gureva T, Eliseev P, Crichton S ,Intira Jeannie Collins IJ, Turkova T, Mariandyshev A, Ritz N

Presented at: The 52nd Union World Conference On Lung Health 2021

View poster


Dec, 2021

REACH project published in CORDIS

Tags: ,

We are proud to announce that the REACH project’s Result in Brief article, Reducing infectious disease in mothers and children in Russia, has been uploaded on the CORDIS website. This is a great opportunity to share our work, with the rest of the world and will ensure that our study results, when available, are available to many. None of what REACH has achieved would have been possible without the collaborative effort of our partners in Europe and the Russian Federation.

Through the joint commitment of our members, the REACH project has drawn to conclusion, having strengthened, and created new international relationships to elevate research opportunities. We must keep this momentum and not waiver in our drive to improve health responses to pandemics and advance our understanding of HIV, TB, and HCV in order to protect pregnant women and children, the vulnerable populations that are usually considered last for clinical trials.

Visit the CORDIS website to read the Results in Brief article





Dec, 2021

Characterisation of the HIV proviral and inducible reservoir in well- suppressed children on long-term ART


Authors: Gärtner K, Byott M, Heaney J, Pagliuzza A, Spyer M.J Frampton D, Rossi A.D, Palmas P, Giaquinto C, Conejo P.R, Foster C,  Rossi P, Klein N, Chomont N, Nastouli E, for the EPIICAL consortium

Presented at: Keystone symposia on molecular and cellular biology

View poster


Dec, 2021

Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial


Authors: Hill L.F, Clements M.N, Turner M.A, Donà D, Lutsar I, Jacqz-Aigrain E, Heath P.T, Roilides E, Rawcliffe L, Alonso-Diaz C, Baraldi E, Dotta A, Ilmoja M, Mahaveer A, Metsvaht T, Mitsiakos G,  Papaevangelou V, Sarafidis K, Walker A.S, Sharland M, on behalf of the NeoVanc Consortium

Published in: The Lancet


Dec, 2021

World AIDS Day 2021: How paediatric HIV has changed in the last 30 years

Tags: ,

It takes a community of people working together to achieve the results we are looking for: eradication HIV in children


The paediatric HIV pandemic has changed from when researchers first began investigating HIV in children to where we stand today.

The burden of perinatal infections, however, remains high. Perinatal infections occur when a pregnant person living with HIV passes HIV to her baby either during pregnancy, delivery or through breastfeeding. Despite unprecedented advances in the prevention of perinatal infections (including those occurring through breastfeeding) utilizing maternal ART and infant post- exposure preventative treatment, new infections continue. An estimated 1.8 million children under 15 years of age are living with HIV-1 globally, and 5 million survive to become adolescents and young adults with perinatal infection. In addition, around 150,000 children are born with HIV-1 annually, with about half of new infections occurring before and during birth and half through breastfeeding. The COVID-19 pandemic, through disruption of clinical care and its economic impact, increased these numbers in 2021 and beyond.

A multidisciplinary, multicultural approach to combat pediatric HIV-1 infection and discover immunotherapeutic strategies towards HIV remission, has been catalyzed by the EPIICAL consortium. The EPIICAL group of investigators and clinicians, through a number of virological and immunological studies conducted both in European HIV infected cohorts as well as in HIV positive African children, has gathered further evidence of efficacy of early therapy to reduce the amount of the virus within individuals and boost of specific immune responses. These studies will pave the way for further therapeutic strategies towards HIV remission using immunotherapeutic approaches.

From the clinical perspective, adherence in mother and child are strongly associated with achieving any therapeutic success. Barriers to the mother taking her therapy often mean that the child will also not be protected! But the mothers, if given the opportunity, do an amazing job at administering therapy to their children. It takes a community of people working together to achieve the results we are looking for and the work of social scientists plays a crucial role in identifying interventions that address non-adherence in mothers and children.

Holly Peay, senior Research Scientist at RTI International and EARTH social and behavioural study lead in EPIICAL, states that “Young children with HIV cannot control their own adherence. It is important to understand attitudes and barriers to adherence experienced by caregivers of children with HIV. That allows us to choose interventions that are targeted to the problems that caregivers experience and gives us hope that improving adherence in children will also improve adherence in their mothers and other HIV positive caregivers.”

The bottom line is, testing should never be delayed and early intervention can save the lives of both mother and the young child because when the mother is suppressed, the child is also likely to be suppressed.

Visit the EPIICAL website to learn more about the project.


We would like to update you on our recent activities